Moa

Novel Agents in Systemic Lupus Erythematosus (AstraZeneca's anifrolumab) and Lupus Nephritis (Aurinia Pharmaceutical's voclosporin and GSK's belimumab) Introduce Paradigm Shifts, According to Spherix Global Insights

Retrieved on: 
Thursday, November 4, 2021
Lupus, Benchmarking, Safety, Surveillance, Thumbay Hospital, IFN, CNI, Clinical trial, MOA, Lupus nephritis, BMS, Pitting corrosion, Nephrology, Anifrolumab, Rheumatology, Woman, Acquisition, JAK, Eli Lilly and Company, Nephritis, Moa, GSK, AstraZeneca, FDA, Patient, Pharmaceutical industry, Fine chemical, Generic drug

For market access issues, there is no consensus regarding the efficacy profiles of the two drugs.

Key Points: 
  • For market access issues, there is no consensus regarding the efficacy profiles of the two drugs.
  • With lupus being two to three times more prevalent in women of color,1 this could be a key advantage for the newly launched brand.
  • The third novel agent to enter the SLE/LN market is Aurinia Pharmaceuticals' Lupkynis (voclosporin), a novel calcineurin inhibitor (CNI) which was approved in January of this year.
  • Whether these three agents can establish a stronghold prior to the wave of incoming pipeline agents for SLE and LN remains in question.

Synaffix Wins World ADC Award for Poster on Efficacy and Tolerability Data on SYNtecan E™-Based ADCs

Retrieved on: 
Thursday, October 28, 2021
Biotechnology, Technology, Control, Industry, Poster, Moa, ADC, Conference, CSO, Company, Therapeutic index, Laboratory, Therapy, Kyowa Hakko Kirin, Aravis, Best, Fine chemical, Pharmaceutical industry

Separately, Synaffix was also awarded 'Runner-Up' for the Best ADC Platform Technology.

Key Points: 
  • Separately, Synaffix was also awarded 'Runner-Up' for the Best ADC Platform Technology.
  • New data presented in the winning poster, titled: "GlycoConnect ADCs Based on Topoisomerase 1 Inhibitor Exatecan (SYNtecan E) Show Excellent In Vivo Efficacy and Tolerability Data" demonstrated complete tumor regression and high tolerability of SYNtecan E based ADCs, and underscores the ability of Synaffix's technologies to enable best-in-class, next generation ADCs.
  • This marks the fifth year that Synaffix' groundbreaking ADC platform technology has been acknowledged at the World ADC Awards ceremony as industry-leading, by a judging panelof world-renowned ADC experts.
  • Both GlycoConnect and HydraSpace are clinical-stage technologies that enable best-in-class ADCs with significantly enhanced efficacy and tolerability.

Synaffix Wins World ADC Award for Poster on Efficacy and Tolerability Data on SYNtecan E™-Based ADCs

Retrieved on: 
Thursday, October 28, 2021
Biotechnology, Technology, Control, Industry, Poster, Moa, ADC, Conference, CSO, Company, Therapeutic index, Laboratory, Therapy, Kyowa Hakko Kirin, Aravis, Best, Fine chemical, Pharmaceutical industry

AMSTERDAM, Oct. 28, 2021 /PRNewswire/ -- Synaffix B.V., a biotechnology company focused on commercializing its clinical-stage platform technology for the development of antibody-drug conjugates (ADCs) with best-in-class therapeutic index today announces that the Company was awarded Best Poster at Hanson Wade's 2021 World ADC Conference. Separately, Synaffix was also awarded 'Runner-Up' for the Best ADC Platform Technology.

Key Points: 
  • Separately, Synaffix was also awarded 'Runner-Up' for the Best ADC Platform Technology.
  • New data presented in the winning poster, titled: "GlycoConnect ADCs Based on Topoisomerase 1 Inhibitor Exatecan (SYNtecan E) Show Excellent In Vivo Efficacy and Tolerability Data" demonstrated complete tumor regression and high tolerability of SYNtecan E based ADCs, and underscores the ability of Synaffix's technologies to enable best-in-class, next generation ADCs.
  • This marks the fifth year that Synaffix' groundbreaking ADC platform technology has been acknowledged at the World ADC Awards ceremony as industry-leading, by a judging panelof world-renowned ADC experts.
  • Both GlycoConnect and HydraSpace are clinical-stage technologies that enable best-in-class ADCs with significantly enhanced efficacy and tolerability.

Synaffix to Present Key ADC Technology Data on SYNtecan ETM Linker-Payload at World ADC Conference

Retrieved on: 
Wednesday, October 13, 2021
Short list, Therapy, CSO, Conference, Biotechnology, Aravis, Control, Industry, ADC, Exatecan, Moa, Mouse, Completeness, Kyowa Hakko Kirin, DNA, Therapeutic index, Research, Technology, Fine chemical

As the ADC community once again comes together to share its latest research, Synaffix is excited to showcase its continued efforts to develop truly best-in-class ADC therapeutics."

Key Points: 
  • As the ADC community once again comes together to share its latest research, Synaffix is excited to showcase its continued efforts to develop truly best-in-class ADC therapeutics."
  • Synaffix B.V. is a biotechnology company that enables ADC product candidates using its clinical-stage, site-specific ADC technology platform.
  • Synaffix' proprietary ADC technology platform consists of GlycoConnect, HydraSpace, and toxSYN technologies.
  • toxSYN is a linker-payload platform that spans key, validated MOAs for ADC product development, including SYNtecan E and SYNeamicin G, among other linker-payloads.

Synaffix to Present Key ADC Technology Data on SYNtecan ETM Linker-Payload at World ADC Conference

Retrieved on: 
Wednesday, October 13, 2021
Short list, Therapy, CSO, Conference, Biotechnology, Aravis, Control, Industry, ADC, Exatecan, Moa, Mouse, Completeness, Kyowa Hakko Kirin, DNA, Therapeutic index, Research, Technology, Fine chemical

AMSTERDAM, Oct. 13, 2021 /PRNewswire/ -- Synaffix B.V., a biotechnology company focused on commercializing its clinical-stage platform technology for the development of antibody-drug conjugates (ADCs) with best-in-class therapeutic index will present new data regarding its topoisomerase 1 inhibitor linker-payload based on exatecan (SYNtecan E™), at the World ADC Conference on 13 October 2021:

Key Points: 
  • As the ADC community once again comes together to share its latest research, Synaffix is excited to showcase its continued efforts to develop truly best-in-class ADC therapeutics."
  • Synaffix B.V. is a biotechnology company that enables ADC product candidates using its clinical-stage, site-specific ADC technology platform.
  • Synaffix' proprietary ADC technology platform consists of GlycoConnect, HydraSpace, and toxSYN technologies.
  • toxSYN is a linker-payload platform that spans key, validated MOAs for ADC product development, including SYNtecan E and SYNeamicin G, among other linker-payloads.

InventHelp Inventor Develops More Accurate Marker (MOA-195)

Retrieved on: 
Monday, April 6, 2020
Birds, Extinct Birds, Moa, Ratites, Dinosaurs

"This inspired me to develop an accessory that could be employed with first-down markers to eliminate discrepancies and delays during games."

Key Points: 
  • "This inspired me to develop an accessory that could be employed with first-down markers to eliminate discrepancies and delays during games."
  • He developed the patent-pending 1ST DOWN to provide a more effective and accurate means of determining first down yardage.
  • This invention could prevent poor measurements that could cost teams a set of down or possessions of the ball.
  • 18-MOA-195, InventHelp, 217 Ninth Street, Pittsburgh, PA 15222, or call (412) 288-1300 ext.

Tyrosine Protein Kinase SYK - Pipeline Review, H1 2020 - ResearchAndMarkets.com

Retrieved on: 
Thursday, February 27, 2020
Health, Pharmaceutical, Birds, Extinct Birds, Analysis, Linguistic description, Linguistics, Moa, Dinosaurs

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

Key Points: 
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
    Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

InventHelp Inventor Develops More Accurate Marker (MOA-195)

Retrieved on: 
Wednesday, February 26, 2020
Birds, Extinct Birds, Moa, Ratites, Dinosaurs

"This inspired me to develop an accessory that could be employed with first-down markers to eliminate discrepancies and delays during games."

Key Points: 
  • "This inspired me to develop an accessory that could be employed with first-down markers to eliminate discrepancies and delays during games."
  • He developed the 1ST DOWN to provide a more effective and accurate means of determining first down yardage.
  • This invention could prevent poor measurements that could cost teams a set of down or possessions of the ball.
  • 18-MOA-195, InventHelp, 217 Ninth Street, Pittsburgh, PA 15222, or call (412) 288-1300 ext.

Global Pipeline Review for Caspase 3 - H1 2020 - ResearchAndMarkets.com

Retrieved on: 
Monday, February 3, 2020
Health, Pharmaceutical, Birds, Extinct Birds, Moa, Ratites, DETAIL, Magazines

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

Key Points: 

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

InventHelp Inventor Develops Safe Exit Light (MOA-220)

Retrieved on: 
Monday, November 11, 2019
Birds, Extinct Birds, Ajax, Ext JS, Moa

"This inspired me to develop a means to more easily find the handles, especially if the vehicle was in an accident."

Key Points: 
  • "This inspired me to develop a means to more easily find the handles, especially if the vehicle was in an accident."
  • He developed the LIGHT WAY to allow individuals to quickly escape the interior after an accident.
  • The original design was submitted to the Mobile sales office of InventHelp.
  • 18-MOA-220, InventHelp, 217 Ninth Street, Pittsburgh, PA 15222, or call (412) 288-1300 ext.